Outlook Therapeutics Inc. (OTLK)
Symbol Info
Listed Symbol OTLK
Name Outlook Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-09-30
Latest Fiscal Revenue $3,087,560
Latest Fiscal EPS $-10.24
Price Info
21 Day Moving Average $1.6556
21 Day EMA $1.699400
50 Day Moving Average $1.9858
50 Day EMA $1.925180
200 Day EMA $3.644020
200 Day Moving Average 3.978030
52 Week High $10.96
52 Week Low $0.85
52 Week Change $-74.120700
Alpha -0.010367
Beta -0.5797
Standard Deviation 0.299046
R2 0.004391
Periods 39
Share Information
10 Day Average Volume 449,963
20 Day Average Volume 491,218
30 Day Average Volume 386,669
50 Day Average Volume 958,232
Outstanding Shares 28,233,484
Float Shares 19,972,351
Percent Float 70.74%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 25
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 354,690
Institute Holdings Percent 2.800000
Institute Sold Previous 3 Months 118,099
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 8,261,133
Price Change
7 Day Price Change $0.2600000
7 Day Percent Change 17.33%
21 Day Price Change $0.1400000
21 Day Percent Change 8.64%
30 Day Price Change $-0.3800001
30 Day Percent Change -17.76%
Month To Date Price Change $0.2300
Month To Date Percent 15.03%
90 Day Price Change $-0.16
90 Day Percent Change -8.33%
Quarter To Date $-0.32
Quarter To Date Percent -15.38%
180 Day Price Change $-5.9968
180 Day Percent Change -77.31%
200 Day Price Change $-6.88
200 Day Percent Change -79.63%
Year To Date $-2.24
Year To Date Percent -56.00%
Profile
Description Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
Details
Issue Type CS
Market Cap $49,690,932
Sec Type
Auditor KPMG LLP
Total Shares Outstanding 28,233,484
CEO
Employees 56
Last Audit UE
Classification
CIK 0001649989
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 7 Clarke Drive
Cranbury, NJ 8512
Website https://www.outlooktherapeutics.com
Facisimile +1 609 228-4330
Telephone +1 609 619-3990
Email jeremy@lifesciadvisors.com
Key Ratios
Profitability
EBIT Margin -1,175.4
EBITDA Margin -1,067.8
Pre-Tax Profit Margin -993.5
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $3,064,476
Revenue Per Share $0.1085
Revenue 3 Years $0.04
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $51,319,544
Price To Sales 16.215149
Price To Free Cash -1.2
PE High Last 5 Years -
Price To Book 50.0
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book -6.9
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 0.8
Leverage Ratio -1.1
Quick Ratio 0.6
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover 0.10
Management Effectiveness
Return Assets -115.68
Return On Equity 395.74
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type
Your Recent History
NASDAQ
OTLK
Outlook Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20190918 09:24:47